Healthcare IT News

HIV Diagnosis Market Report Provides a Comprehensive Analysis of Current and Future Market Trends, And Emerging Revenues for the Growth Opportunities

Press Release

 

According to a new market research report “Global HIV Diagnosis Market Size, Share, Development, Growth and Demand Forecast to 2023 – Industry Insight by Product (Consumables, Instruments and Software & Services), by Type of Test (Antibody Test, Viral Load, CD4, Early Infant Diagnosis and Viral Identification), by End User (Diagnostic Laboratories, Hospitals, Research Institutes and Others)” published by P&S Intelligence, the global HIV diagnosis market is expected to grow at a CAGR of 10.6%, during 2017 – 2023.

As per the findings of the research, based on products, consumables segment is the largest product category in the global HIV diagnosis market. Antibody test has been the largely performed test of the global HIV diagnosis market, followed by viral load, CD4, early infant diagnosis and viral identification. Diagnostic laboratories have been the largest end user of HIV diagnosis, followed by hospitals, research institutes and others.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/hiv-diagnosis-market/report-sample

Geographically, North America has been the largest market for HIV diagnosis, with the U.S. being the largest contributor to the regional market. Increasing prevalence of HIV/AIDS and advantageous features of point of care instruments and kits have been driving the growth of the North American market. In Europe, the U.K. has been the largest contributor to the market for HIV diagnosis, followed by Germany and France. The HIV diagnosis market is expected to witness the fastest growth in Asia-Pacific, during 2017 – 2023, owing to increasing cases of HIV, rising healthcare expenditure and increasing frequency of blood transfusions.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=hiv-diagnosis-market

In recent years the USFDA has approved some home-based HIV diagnosis kits that can provide a HIV test result within 20 to 40 minutes, without having the need for sending the test sample to a laboratory. The home-based HIV diagnosis devices offer a number of advantages over the standard HIV diagnosis procedure since they are more convenient to use, save time and are less costly which has made them increasingly popular in countries such as the U.S. and the U.K. The availability of the home-based tests is expected to contribute significantly in helping more infected people become aware of their HIV status and thereby tapping the untapped potential of HIV diagnosis market. Some of the home-based kits approved by the USFDA include Home Access HIV-1 Test System and OraQuick In-Home HIV Test. This provides an opportunity to the players to further strengthen their current and potential markets, launching low-cost and easy to use HIV diagnosis devices that can be used at home by the consumers.

Some of the key players in the HIV diagnosis market include Siemens AG, F. Hoffman La Roche Ltd., Danaher Corporation, Abbott Laboratories, Ltd., Thermo-Fisher Scientific Inc., Merck KGaA, Becton, Dickinson & Company, Alere Inc., Bio-Rad Laboratories and Hologic Inc.